Evaluation of a Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 114,165 people enrolled
- Started
- 21 Oct 2024
- Ended
- 30 Apr 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Patient letter and clinician communication
- Record updated
- 5 August 2025
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients 19 years and older
- Patients empaneled to 1 of 8 adult primary care practices as of September 2024
Who cannot take part
- Patients 18 years or younger
- Patients not empaneled to 1 of 8 adult primary care practices as of September 2024
Where in United States
- Mayo ClinicRochester, United States
About the trial
What the trial wants to find out
The study will test two tactics to improve uptake of two vaccines in adults. The vaccines prevent COVID-19 and influenza. Both are common and harmful. Most adults do not get either vaccine. This is despite strong recommendations that all adults get both vaccines.
Read full original descriptionShow less
The study will involve adult patients at eight Mayo Clinic primary care practices in Rochester and Kasson. The study will test the two tactics together. Four clinics will get the two tactics. The other four clinics will not. The study will randomly assign the two tactics to the clinics. One tactic is to send a letter by US mail to the patient. The letter will state strong recommendations on getting both vaccines now. It will tell patients how to get the vaccines now. The second tactic is to send monthly emails to clinicians. It will remind them to use every visit to vaccinate patients against COVID-19 and influenza. The study will compare the uptake of the two vaccines after six months in the clinics with and without the two tactics.
The 2 groups in the trial
- Patient letter and clinician communicationTreatment being tested
Each patient will be mailed a letter and each patient's clinician will receive a monthly email communicating information about making a strong recommendation for influenza and COVID-19 vaccination
- No interventionNo study treatment, for comparison
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 5 August 2025